GlassScriptPhysician profile
Prerna Mewawalla
NPI 1689804510
$27,903.88
in general payments reported to CMS, 2019-2025
15 companies · $21K in 2025
The $21K reported for 2025 was more than what 93% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $87.49 · 2020: $63.41 · 2023: $4,419 · 2024: $2,059 · 2025: $21K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $24K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,572 · Food and Beverage: $1,253.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $23,928.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,571.81 |
| Food and Beverage | $1,253.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $15,278.60 | 2024-2025 | |
| Janssen Biotech, INC. | $8,895.83 | 2023-2025 | Tecvayli, Talvey, Carvykti |
| E.R. Squibb & Sons, L.L.C. | $2,422.00 | 2023 | |
| Janssen Scientific Affairs, LLC | $735.00 | 2023-2024 | Darzalex, Talvey |
| Glaxosmithkline, LLC. | $200.43 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $87.49 | 2019 | |
| Jazz Pharmaceuticals INC. | $63.41 | 2020 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $61.50 | 2023 | Lifevest |
| Adaptive Biotechnologies Corporation | $49.75 | 2025 | Clonoseq |
| Axsome Therapeutics, INC. | $35.00 | 2025 | Auvelity |
| Incyte Corporation | $25.57 | 2025 | Zynyz, Monjuvi |
| Kite Pharma, INC. | $19.41 | 2025 | Yescarta |
| Beigene USA, INC. | $15.72 | 2024 | Brukinsa |
| Regeneron Pharmaceuticals, INC. | $14.17 | 2025 | Lynozyfic |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Prerna Mewawalla listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.